Heras Magda, Sionis Alessandro
Institut Clinic de Malalties Cardiovasculars, Hospital Clinic, Barcelona, Spain.
Drugs Today (Barc). 2003 Apr;39(4):249-64. doi: 10.1358/dot.2003.39.4.799402.
Given the importance of thrombosis in acute coronary syndromes, antithrombotic therapy has become standard treatment for these conditions. This article reviews the mechanism of action and the major evidence supporting the clinical use of clopidogrel, a potent antiplatelet agent of the thienopyridines class, focusing on its role in the setting of acute coronary syndromes without persistent ST segment elevation (unstable angina and non-Q wave myocardial infarction). Some unanswered questions relating to this medication are also highlighted. Finally, current updates on clinical guidelines for the use of clopidogrel in acute coronary syndromes are discussed.
